Literature DB >> 17562983

The Boston keratoprosthesis in herpetic keratitis.

Bilal F Khan1, Mona Harissi-Dagher, Deborah Pavan-Langston, James V Aquavella, Claes H Dohlman.   

Abstract

OBJECTIVE: To evaluate the role of an artificial cornea (Boston Keratoprosthesis [KPro]) in herpetic corneal graft failures.
METHODS: A series of 17 herpetic eyes of 14 patients with failed transplantations, treated with implantation of a corneal graft with a KPro, was reviewed. Outcomes measured were retention of the device, visual acuity at 1 week, best visual acuity, last assessed visual acuity, time of follow-up, and complications.
RESULTS: Follow-up ranged between 6 and 72 months (median, 14 months). All patients had improvement in postoperative visual acuity, with 16 (94%) of 17 eyes getting better than preoperative visual acuity within 1 week. Of the 17 eyes, 15 (88%) achieved a best visual acuity of 20/25 to 20/70 and, at the last examination, 11 eyes (73%) were still in that range. Four patients with prolonged preoperative inflammation and ulceration at KPro placement had resolution of inflammation within days. The KPro had no extrusions. Complications included retroprosthesis membrane in 3 eyes and 1 tissue melt in an early case.
CONCLUSIONS: The KPro can be of value in patients with graft failure from herpetic keratitis, even in the inflamed stage. We believe that herpetic keratitis is not a contraindication for KPro use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562983     DOI: 10.1001/archopht.125.6.745

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  10 in total

1.  Boston type 1 keratoprosthesis: the New York Eye and Ear experience.

Authors:  A P Patel; E I Wu; D C Ritterband; J A Seedor
Journal:  Eye (Lond)       Date:  2011-12-16       Impact factor: 3.775

Review 2.  Fungal Infections After Boston Type 1 Keratoprosthesis Implantation: Literature Review and In Vitro Antifungal Activity of Hypochlorous Acid.

Authors:  Silvia Odorcic; Wolfgang Haas; Michael S Gilmore; Claes H Dohlman
Journal:  Cornea       Date:  2015-12       Impact factor: 2.651

3.  Artificial corneas versus donor corneas for repeat corneal transplants.

Authors:  Masako Chen; Sueko M Ng; Esen K Akpek; Sumayya Ahmad
Journal:  Cochrane Database Syst Rev       Date:  2020-05-13

Review 4.  High-risk corneal allografts: A therapeutic challenge.

Authors:  Tian Yu; Vijayalakshmi Rajendran; May Griffith; John V Forrester; Lucia Kuffová
Journal:  World J Transplant       Date:  2016-03-24

Review 5.  Artificial corneas versus donor corneas for repeat corneal transplants.

Authors:  Esen K Akpek; Majed Alkharashi; Frank S Hwang; Sueko M Ng; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2014-11-05

Review 6.  The treatment of end-stage corneal disease: penetrating keratoplasty compared with Boston type 1 keratoprosthesis.

Authors:  Steven Bonneau; C Maya Tong; Yelin Yang; Mona Harissi-Dagher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-04-06       Impact factor: 3.535

7.  Donor Corneal Transplantation vs Boston Type 1 Keratoprosthesis in Patients with Previous Graft Failures: A Retrospective Single Center Study (An American Ophthalmological Society Thesis).

Authors:  Esen K Akpek; Sandra D Cassard; Karen Dunlap; Sarah Hahn; Pradeep Y Ramulu
Journal:  Trans Am Ophthalmol Soc       Date:  2015

8.  Toward electron-beam sterilization of a pre-assembled Boston keratoprosthesis.

Authors:  Sina Sharifi; Hannah Sharifi; Curtis Guild; Mohammad Mirazul Islam; Khoa D Tran; Corrina Patzer; Claes H Dohlman; Eleftherios I Paschalis; Miguel Gonzalez-Andrades; James Chodosh
Journal:  Ocul Surf       Date:  2021-03-03       Impact factor: 5.033

9.  Acute retinal necrosis after Boston type I keratoprosthesis.

Authors:  Abdullah M Al-Amri; Saba Al-Rashaed; Sulaiman Al-Kharashi
Journal:  Middle East Afr J Ophthalmol       Date:  2012 Apr-Jun

10.  Eight-years Egyptian experience of Boston type I keratoprosthesis following failed penetrating keratoplasty or ocular surface disease.

Authors:  Ihab S Othman; Hesham M Gharieb; Hani M G Ibrahim
Journal:  Saudi J Ophthalmol       Date:  2022-07-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.